Cancer Research and Treatment

Joo-Hyun Nam

2 Articles

Fatal Ifosfamide-Induced Metabolic Encephalopathy in Patients with Recurrent Epithelial Ovarian Cancer: Report of Two Cases: You-Jung Shin, Ji-Young Kim, Jei-Won Moon, Rae-Mi You, Jeong-Yeol Park, Joo-Hyun Nam; Cancer Res Treat. 2011;43(4):260-263. Published online December 27, 2011; DOI: https://doi.org/10.4143/crt.2011.43.4.260

Central nervous system (CNS) toxicity has been reported in approximately 10-30% of patients receiving intravenous infusions of ifosfamide. Encephalopathy is a rare but serious CNS adverse reaction in these patients, and although usually transient and reversible, may cause persistent neurological dysfunction or death. Clinical features range from fatigue and confusion to coma and death. Although methylene blue can be used to treat ifosfamide-induced neurotoxicity, including encephalopathy, its mechanism of action remains poorly defined. We describe here two patients with recurrent epithelial ovarian cancer who experienced fatal encephalopathy following ifosfamide/mesna treatment.

Citations

Citations to this article as recorded by

Rare Delayed Ifosfamide Encephalopathy: A Case Report of Chemotherapeutic Neurotoxicity
Ambika Menon, Chidiebele A. Enunwa, William L. Read, Kyle P. James
Case Reports in Oncology.2024; 17(1): 202. CrossRef
Potential of Cytochrome P450, a Family of Xenobiotic Metabolizing Enzymes, in Cancer Therapy
Ragini D. Singh, Avadhesh Avadhesh, Gaurav Sharma, Sagar Dholariya, Rima B. Shah, Bela Goyal, Subash Chandra Gupta
Antioxidants & Redox Signaling.2023; 38(10-12): 853. CrossRef
Ifosfamide - History, efficacy, toxicity and encephalopathy
Jeffrey R. Idle, Diren Beyoğlu
Pharmacology & Therapeutics.2023; 243: 108366. CrossRef
A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant
Tomomi Sano, Nokitaka Setsu, Eisuke Kobayashi, Akira Kawai
YAKUGAKU ZASSHI.2023; 143(6): 541. CrossRef
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies
Ali Zarrabi, David Perrin, Mahboubeh Kavoosi, Micah Sommer, Serap Sezen, Parvaneh Mehrbod, Bhavya Bhushan, Filip Machaj, Jakub Rosik, Philip Kawalec, Saba Afifi, Seyed Mohammadreza Bolandi, Peiman Koleini, Mohsen Taheri, Tayyebeh Madrakian, Marek J. Łos,
Cancers.2023; 15(21): 5269. CrossRef
Ifosfamide-induced Encephalopathy With Rapid Response to Thiamine: A Pediatric Case
Eren Müngen, İnci Yaman Bajin, Sibel Öz, Ceren Günbey, Banu Anlar, Burca Aydin
Journal of Pediatric Hematology/Oncology.2022; 44(7): 402. CrossRef
Methylene blue and ifosfamide-induced encephalopathy: Myth or reality?
Halima Abahssain, Badreddine Moukafih, Hajar Essangri, Hind Mrabti, Bouchra Meddah, Fadila Guessous, Fatima Zahra Fadhil, Amine Souadka, Hassan Errihani
Journal of Oncology Pharmacy Practice.2021; 27(1): 143. CrossRef
Effect of Berberis vulgaris L. root extract on ifosfamide-induced in vivo toxicity and in vitro cytotoxicity
Shazia Ilyas, Raheela Tabasum, Ali Iftikhar, Mamoona Nazir, Amina Hussain, Aroosha Hussain, Muhammad Sajjad Ali, Farooq Saleem, Uzma Saleem, Matheus Froeyen, Iskandar Abdullah, Muhammad Usman Mirza, Sarfraz Ahmad
Scientific Reports.2021;[Epub] CrossRef
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer
Eda Ataseven, Şebnem Önen Göktepe, Mehmet Kantar
Journal of Oncology Pharmacy Practice.2021; 27(8): 2018. CrossRef
Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Claudia Pellacani, Georgios Eleftheriou
Advances in Medical Sciences.2020; 65(2): 265. CrossRef
Delayed Ifosfamide Neurotoxicity
Jill Yeager, Alina Basnet
American Journal of Therapeutics.2020; 27(6): e613. CrossRef
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy
Aaron M. Gusdon, Rachna Malani, Xi Chen
Journal of Clinical Neurophysiology.2019; 36(2): 150. CrossRef
Incidence et facteurs de risque de l’encéphalopathie à l’ifosfamide chez les patients suivis pour un sarcome
Natacha Stern, Ilyes Sakji, Anne-Sophie Defachelles, Cyril Lervat, Thomas Ryckewaert, Guillaume Marliot, Charlotte Peugniez, Dominique Deplanque, Nicolas Penel
Bulletin du Cancer.2017; 104(3): 208. CrossRef
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis
Yin Lo, Li-Jiuan Shen, Wen-Hwei Chen, Yaa-Hui Dong, Fe-Lin Lin Wu
Journal of the Formosan Medical Association.2016; 115(9): 744. CrossRef
The Neurotoxicity and Pharmacokinetics of Oral Ifosfamide
Martin S. Highley, Guido Momerency, Diane Sawyers, Ernst A. De Bruijn, Hans Prenen, Gunther Guetens, Gert De Boeck, Allan T. Van Oosterom, Janine L. Mansi, Peter R. Blake, Tim Mant, Robert A.A. Maes , Peter G. Harper
Journal of Analytical Oncology.2015;[Epub] CrossRef
Ifosfamide related encephalopathy: The need for a timely EEG evaluation
Anteneh M. Feyissa, Sudhakar Tummala
Journal of the Neurological Sciences.2014; 336(1-2): 109. CrossRef
PharmGKB summary
Daniella Lowenberg, Caroline F. Thorn, Zeruesenay Desta, David A. Flockhart, Russ B. Altman, Teri E. Klein
Pharmacogenetics and Genomics.2014; 24(2): 133. CrossRef
Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant
Alice Séjourné, Sabine Noal, Mathieu Boone, Céline Bihan, Marion Sassier, Michel Andrejak, Bruno Chauffert
Case Reports in Oncology.2014; 7(3): 669. CrossRef

13,887 View
111 Download
18 Crossref

A Preliminary Results of a Randomized Trial Comparing Monthly 5-flourouracil and Cisplatin to Weekly Cisplatin Alone Combined with Concurrent Radiotherapy for Locally Advanced Cervical Cancer: Young Seok Kim, Seong Soo Shin, Eun Kyung Choi, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Heon-Jin Park, Young-Tak Kim, Jung-Eun Mok, Joo-Hyun Nam; Cancer Res Treat. 2005;37(1):37-43. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.37

Abstract PDF PubReader ePub

Purpose

To determine the superior chemotherapeutic regimen between monthly 5-FU plus cisplatin (FP) and weekly cisplatin alone in concurrent chemoradiotherapy for locally advanced cervical cancer, the compliance of treatment, response, survival and toxicities were analyzed between the two arms.

Materials and Methods

Between March 1998 and December 2001, 61 patients with locally advanced cervical cancer (stage IIB through IVA) and negative para-aortic lymph nodes were randomly assigned to either 'monthly FP' (arm I, n=34) or 'weekly cisplatin' (arm II, n=27) with concurrent radiotherapy. The patients of arm I received FP (5-FU 1,000 mg/m²/day + cisplatin 20 mg/m²/day, for 5 days, for 3 cycles at 4 week intervals) and those of arm II received cisplatin (30 mg/m²/day, for 6 cycles at 1 week intervals) with concurrent radiotherapy. The radiotherapy consisted of 41.4~50.4 Gy external beam irradiation in 23~28 fractions to the whole pelvis, with high dose rate brachytherapy delivering a dose of 30~35 Gy in 6~7 fractions to point A. During the brachytherapy, a parametrial boost was delivered. The median follow-up period for survivors was 44 months.

Results

The compliance of treatment in monthly FP weekly cisplatin arms were 62 and 81%, respectively. The complete response rates at 3 months were 96 and 88% in arms I and II, respectively. The 4-year overall survival and disease free survival rates were 64 and 54% in the arm I and 77 and 66% in the arm II, respectively. The incidence of hematologic toxicity more than grade 2 was 29% in the arm I and 15% in the arm II. Only one patient in arm I experienced grade 3 gastrointestinal toxicity. No severe genitourinary toxicity was observed.

Conclusion

No significant difference was observed in the compliance, responses, survival rates and acute toxicities between the two treatment arms. More patients and further follow up will be required.

Citations

Citations to this article as recorded by

American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer
Jyoti Mayadev, Akila Viswanathan, Yu Liu, Chin-Shang Li, Kevin Albuquerque, Antonio L. Damato, Sushil Beriwal, Beth Erickson
Brachytherapy.2017; 16(1): 22. CrossRef
Concurrent Weekly Cisplatin Versus Triweekly Cisplatin with Radiotherapy in the Treatment of Cervical Cancer: A Meta-analysis Result
Yan Hu, Zhi-Qiang Cai, Xiao-Yan Su
Asian Pacific Journal of Cancer Prevention.2012; 13(9): 4301. CrossRef
Laparoscopy-Assisted Intracavitary Radiotherapy Tandem Placement for Patients With Cervical Cancer
Myong Cheol Lim, Dae Chul Jung, Joo-Young Kim, Sang-Yoon Park
International Journal of Gynecologic Cancer.2009; 19(6): 1125. CrossRef
Adoptive Transfer of Human Papillomavirus E7-specific CTL Enhances Tumor Chemoresponse Through the Perforin/Granzyme-mediated Pathway
Jeong-Im Sin, Jung-Min Kim, Sung Hwa Bae, In Hee Lee, Jong Sup Park, Hun Mo Ryoo
Molecular Therapy.2009; 17(5): 906. CrossRef

9,699 View
56 Download
4 Crossref

Author index